Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  4Sc AG    VSC   DE000A14KL72

4SC AG (VSC)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Tradegate - 06/21 04:13:42 pm
4.655 EUR   -0.43%
05/224SC AG : 9 upcoming conferences and roadshows
EQ
04/264SC : provides Q1 2018 update
EQ
04/194SC AG : Phase II study of 4SC's resminostat in biliary tract cancer..
EQ
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Xetra
06/15/2018 06/18/2018 06/19/2018 06/20/2018 06/21/2018 Date
4.66(c) 4.96(c) 4.8(c) 4.675(c) 4.7 Last
49 485 28 530 15 894 26 540 11 119 Volume
-5.48% +6.44% -3.23% -2.60% +0.53% Change
More quotes
Financials (EUR)
Sales 2018 5,95 M
EBIT 2018 -15,2 M
Net income 2018 -14,8 M
Finance 2018 29,1 M
Yield 2018 -
Sales 2019 5,65 M
EBIT 2019 -15,5 M
Net income 2019 -15,2 M
Finance 2019 19,9 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 20,7x
EV / Sales2019 23,4x
Capitalization 152 M
More Financials
Company
4SC AG engages in the development of small molecule drugs that targets cancer through epigenetic mechanisms.It also involves in the preclinical and clinical development of its products.Its assets are resminostat, 4SC-202, and 4SC-208.The company was founded by Ulrich Dauer, Daniel Vitt, Stefan... 
More about the company
Surperformance© ratings of 4Sc AG
Trading Rating : Investor Rating :
More Ratings
Latest news on 4SC AG
05/224SC AG : 9 upcoming conferences and roadshows
EQ
04/264SC : provides Q1 2018 update
EQ
04/194SC AG : Phase II study of 4SC's resminostat in biliary tract cancer in Japan is..
EQ
04/174SC AT AACR : Broadened clinical options for 4SC-202
EQ
04/114SC AG : Yakult Honsha recruits first Japanese patient in 4SC's pivotal RESMAIN ..
EQ
03/274SC : Yakult Honsha joins 4SC's pivotal RESMAIN study of resminostat in CTCL - 4..
EQ
03/214SC : announces results for financial year 2017
EQ
03/154SC : Patent Issued for Substituted Imidazoquinolines (USPTO 9908880)
AQ
03/154SC AG : Conference call to be hosted on 21 March 2018 to present the financial ..
EQ
03/134SC AG : Preliminary announcement of the publication of financial reports accord..
EQ
More news
Sector news : Biotechnology & Medical Research - NEC
02:59pGILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
08:02aLatecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
05/224SC AG: 9 upcoming conferences and roadshows  
05/224SC AG: 9 upcoming conferences and roadshows
1
05/03$VSC #4 SC AG 4SC - Yakult starts Phase II trial; fresh 4SC-202 data: Yakult,.. 
04/264SC : provides Q1 2018 update  
04/264SC provides Q1 2018 update
1
More tweets
Qtime:34
News from SeekingAlpha
02/064SC (FSCGF) Presents At BioCapital Europe 2018 - Slideshow 
02/033 THINGS IN BIOTECH YOU SHOULD LEARN : February 2, 2018 
20164SC AG Presents at The German Equity Forum 2016 
Chart 4SC AG
Duration : Period :
4Sc AG Technical Analysis Chart | VSC | DE000A14KL72 | 4-Traders
Technical analysis trends 4SC AG
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price -
Spread / Average Target -100%
EPS Revisions
Managers
NameTitle
Jason Loveridge Chief Executive Officer
Clemens M. Doppler Chairman-Supervisory Board
Susanne Danhauser-Riedl Chief Medical Officer
Manfred Rüdiger Member-Supervisory Board
Helmut Jeggle Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
4SC AG-0.06%176
CELLTRION, INC.--.--%34 574
IQVIA HOLDINGS INC8.22%21 638
LONZA GROUP1.10%20 183
INCYTE CORPORATION-23.96%15 266
ALNYLAM PHARMACEUTICALS, INC.-17.65%10 678